MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today announced completion of enrollment in RESOLUTE International, a post-market study of its Resolute Drug-Eluting Stent (DES). One-year data from this international study, which enrolled 2,464 patients at 88 sites from 17 countries in Europe, Asia, Africa, and Latin America, are expected in the second half of 2010.
